National Insurance Coverage Begins April 1

Polish Society of Clinical Oncology Selected Therapy for Priority Reimbursement List Last Month

The combination therapy using Lekraza (ingredient: lazertinib) and Rybrevant (ingredient: amivantamab), which the Polish oncology community had previously listed as a top reimbursement priority, has now actually been included in the national health insurance coverage.

Product image of Yuhan Corporation's lung cancer treatment drug Leclaza. Yuhan Corporation

Product image of Yuhan Corporation's lung cancer treatment drug Leclaza. Yuhan Corporation

View original image

According to Polish health authorities, the new reimbursement list that went into effect on April 1 now includes the combination therapy of Lekraza and Rybrevant.


Last month, the Polish Society of Clinical Oncology (PTOK) selected the combination of Lekraza and Rybrevant as a top-priority anticancer therapy for first-line treatment of EGFR-mutant non-small cell lung cancer in its "TOP 10 ONKO 2026" recommendations.


Expert recommendations were swiftly reflected in policy. With this new reimbursement policy, Polish patients with advanced non-small cell lung cancer who have either the EGFR exon 19 deletion or L858R mutation are now eligible for national insurance coverage for the first-line combination therapy of lazertinib and amivantamab.


Each year, PTOK identifies technologies with the greatest clinical need and sets reimbursement priorities, ranking them based on clinical urgency, treatment efficacy, and the potential to improve patient access. The priority list focuses not just on the need for new drugs but on their real impact on treatment outcomes.


This year's list includes a total of 10 treatment strategies, covering major cancer types such as lung, colorectal, liver, breast, and prostate cancers. In addition to the Lekraza and Rybrevant combination therapy, the reimbursement priority list also includes combination therapy with Imfinzi (ingredient: durvalumab) and Imjudo (ingredient: tremelimumab) for hepatocellular carcinoma.



Maciej Krzakowski, President of PTOK, commented on the priority reimbursement list, saying, "We select treatments that have strong scientific evidence yet are still not being sufficiently utilized."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing